Intraaortic balloon assistance in intractable cardiogenic shock

Moulopoulos, Spyridon D.; Stamatelopoulos, S.; Petrou, Panagiotis

doi:10.1093/oxfordjournals.eurheartj.a062080

Cited by 53 publications

(23 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, we believe that the recommendation of combining IABC and TT on the basis of a few nonrandomized studies that have shown better outcomes than with TT alone [11][12][13][14][15] is not a firmly evidencebased position. This issue will need to be properly addressed in studies directly comparing IABC as an adjunct to TT with IABC alone.…”

Section: Discussionmentioning

confidence: 99%

“…It has been suggested that IABC can improve coronary flow and patency by increasing the diastolic perfusion pressure [8][9][10]. In retrospective [11][12][13][14][15] as well as prospective [4] nonrandomized studies, IABC combined with TTwas associated with a significantly higher survival than TT alone. Yet, in the SHOCK Trial Registry [4], the largest prospective series of patients with post-MI cardiogenic shock, IABC combined with TT conferred no survival benefit when compared with IABC alone.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Intra-aortic balloon counterpulsation and delayed revascularization for myocardial infarction and shock in the absence of primary angioplasty: a treatment strategy with or without thrombolysis?

Drakos

Anastasiou-Nana²,

Terrovitis³

et al. 2008

Coronary Artery Disease

View full text Add to dashboard Cite

In patients presenting with acute MI and cardiogenic shock, TT as an adjunct to IABC added no therapeutic benefit when compared with IABC alone. In contrast, the survival of patients was significantly increased by delayed invasive revascularization in both treatment groups. These observations suggest that, when revascularization facilities are not available, stabilization with IABC, followed by prompt transfer for delayed revascularization to a tertiary care hospital, might be the preferred management strategy for patients presenting with post-MI cardiogenic shock.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Intra-aortic balloon counterpulsation and delayed revascularization for myocardial infarction and shock in the absence of primary angioplasty: a treatment strategy with or without thrombolysis?

Drakos

Anastasiou-Nana²,

Terrovitis³

et al. 2008

Coronary Artery Disease

View full text Add to dashboard Cite

show abstract

“…Since then, several observational series have supported the potential benefits of the IABP in patients with AMI treated with thrombolytic therapy and complicated by cardiogenic shock [44][45][46].…”

Section: Cardiogenic Shockmentioning

confidence: 99%

Aortic counterpulsation: A review of the hemodynamic effects and indications for use

Santa-Cruz

Cohen

Ohman

2005

Cathet Cardio Intervent

View full text Add to dashboard Cite

In the ever evolving field of cardiovascular medicine and coronary intervention, the intra-aortic balloon pump (IABP) is a mature technology, which still plays an important role. The balloon pump invasively supports patient hemodynamics by augmenting diastolic perfusion and increasing diastolic blood pressure, thereby increasing coronary perfusion and reducing afterload. Its efficacy has been demonstrated in a multitude of clinical situations, including acute coronary syndromes, high-risk coronary interventions, cardiogenic shock, and cardiovascular surgery. The potential complications of aortic counterpulsation are serious, although much lower than once feared. With proper patient selection, insertion technique, and management, the IABP is a powerful tool to assist in the treatment of patients with cardiovascular disease. This article will review the hemodynamics, indications, and complications associated with its use.

show abstract

“…CS postacute myocardial infarction (AMI) has a prevalence varying between 5 and 15% with an associated mortality close to 50% in most recent studies [1]. Management of CS in AMI consists of early revascularization either by percutaneous coronary intervention (PCI) or coronary bypass grafting as well as constant hemodynamic support with use of inotropic agents, vasopressors and percutaneous ventricular assist devices such as the intra-aortic balloon pump (IABP) [2,3]. These measures are aimed to improve cardiac output (CO) and to prevent the deleterious consequences of multi-organ failure and the systemic inflammatory response that ensues.…”

mentioning

confidence: 99%

“…IABP is the commonly used peripherally inserted ventricular assist device in the setting of CS complicating AMI [2]. IABP is placed in the descending thoracic aorta via femoral arterial access.…”

mentioning

confidence: 99%

Supporting the failing myocardium: is intra-aortic balloon pump enough? The IABP-SHOCK II trial

Negi

Kar

Gregorič

et al. 2013

Expert Review of Cardiovascular Therapy

View full text Add to dashboard Cite

Cardiogenic shock (CS) in acute myocardial infarction (AMI) is associated with high mortality. Ventricular support devices such as intra-aortic balloon pumps have been used in the acute management of this condition. However, a recent randomized controlled trial conducted by Thiele et al. showed that the use of an intra-aortic balloon pump in CS in AMI does not improve 30-day outcomes in these patients. In the following review, the authors discuss the salient features of the article, how the results of this trial are likely to change the management strategies in CS in the setting of AMI and the future directions.

show abstract

Intraaortic balloon assistance in intractable cardiogenic shock

Cited by 53 publications

References 0 publications

Intra-aortic balloon counterpulsation and delayed revascularization for myocardial infarction and shock in the absence of primary angioplasty: a treatment strategy with or without thrombolysis?

Intra-aortic balloon counterpulsation and delayed revascularization for myocardial infarction and shock in the absence of primary angioplasty: a treatment strategy with or without thrombolysis?

Aortic counterpulsation: A review of the hemodynamic effects and indications for use

Supporting the failing myocardium: is intra-aortic balloon pump enough? The IABP-SHOCK II trial

Contact Info

Product

Resources

About